Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Breast cancer genomic subtype-specific copy number alterations in metastases.

Scientific reports·2026
Same author

Real-time cell viability monitoring for high-throughput drug screening using tumor xenograft-derived cells.

Cell reports methods·2026
Same author

AI-predicted spatial transcriptomics unlocks breast cancer biomarkers from pathology.

Cell·2026
Same author

A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence.

NPJ breast cancer·2026
Same author

[Antibody drug conjugates: Use and optimization in HER2-negative metastatic breast cancers (triple negative, RH+/HER2-)].

Bulletin du cancer·2026
Same author

Compartment-specific tumor-infiltrating immune cells and prognosis in breast cancer.

iScience·2026

Related Experiment Video

Updated: May 6, 2026

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

8.2K

Assessing excellence in translational cancer research: a consensus based framework.

Abinaya Rajan, Carlos Caldas, Henri van Luenen

  • 1The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands. w.v.harten@nki.nl.

Journal of Translational Medicine
|October 31, 2013
PubMed
Summary

Developing an excellence framework for translational cancer research in Europe involved extensive stakeholder consensus. This framework prioritizes qualitative process evaluation over quantitative outputs to enhance cancer research efficiency and patient benefit.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K
Working with Human Tissues for Translational Cancer Research
07:48

Working with Human Tissues for Translational Cancer Research

Published on: November 26, 2015

9.7K

Related Experiment Videos

Last Updated: May 6, 2026

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

8.2K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K
Working with Human Tissues for Translational Cancer Research
07:48

Working with Human Tissues for Translational Cancer Research

Published on: November 26, 2015

9.7K

Area of Science:

  • Oncology
  • Translational Research
  • Health Services Research

Background:

  • Translational cancer research faces delays in delivering patient benefits.
  • Expert-based excellence assessment can identify high-performing centers and best practices.
  • Improving translational research efficiency can foster networks and partnerships.

Purpose of the Study:

  • To develop an excellence assessment framework for translational cancer research in Europe.
  • To build consensus among diverse stakeholders on assessment criteria.
  • To improve the quality and efficiency of the translational cancer research process.

Main Methods:

  • Systematic review of existing translational research models.
  • European stakeholder survey and focus groups to score and refine criteria.
  • Expert group meetings and independent review by the European Academy of Cancer Sciences.

Main Results:

  • An 18-criterion framework across 6 themes was developed.
  • Stakeholders favored qualitative criteria assessing the research process.
  • Criteria include clinician-basic researcher involvement and well-designed clinical trials.

Conclusions:

  • The framework is a product of intense stakeholder consensus.
  • It will be piloted in European Comprehensive Cancer Centres.
  • Findings may inform other clinical and research fields.